- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04628767
Prüfung der Zugabe von MEDI4736 (Durvalumab) zur Chemotherapie vor einer Operation bei Patienten mit hochgradigem Krebs der oberen Harnwege
Eine Phase-II/III-Studie mit MEDI4736 (Durvalumab) und Chemotherapie für Patienten mit hochgradigem Urothelkarzinom der oberen Harnwege vor Nephroureterektomie
This phase II/III trial compares the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery in treating patients with upper urinary tract cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as methotrexate, vinblastine, doxorubicin, cisplatin, and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Durvalumab in combination with chemotherapy before surgery may enhance the shrinking of the tumor compared to chemotherapy alone.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
- Arzneimittel: Cisplatin
- Verfahren: Biospecimen Collection
- Arzneimittel: Methotrexate
- Verfahren: Computed Tomography
- Verfahren: Magnetic Resonance Imaging
- Arzneimittel: Gemcitabine Hydrochloride
- Verfahren: Therapeutic Conventional Surgery
- Verfahren: Biopsy Procedure
- Biologisch: Durvalumab
- Arzneimittel: Doxorubicin Hydrochloride
- Biologisch: Pegfilgrastim
- Arzneimittel: Vinblastine Sulfate
Detaillierte Beschreibung
PRIMARY OBJECTIVES:
I. To compare event-free survival (EFS) between patients with upper tract urothelial cancer (UTUC) randomized to neoadjuvant accelerated methotrexate, vinblastine, Adriamycin, cisplatin (aMVAC) alone or in combination with durvalumab. (Cisplatin eligible patients [Arms A and B]) II. Evaluation of pathologic complete response at radical nephroureterectomy (RNU) (pathologic complete response [pCR], ypT0N0/Nx). (Cisplatin ineligible patients [Arm C]).
SECONDARY OBJECTIVES:
I. To assess pathologic complete response (pCR) at surgery. (Cisplatin eligible cohort) II. Event-free survival (EFS) will be evaluated for the cisplatin ineligible cohort as a secondary endpoint. (Cisplatin ineligible cohort) III. Overall survival in all, and by post chemotherapy response (ypT0N0, yp =< T1N0, yp >= T2Nany). (All patients) IV. To evaluate disease-free survival (DFS) in each arm of the trial separately. (All patients) V. To evaluate cancer-specific survival of patients in each arm of the trial separately. (All patients) VI. To evaluate renal function outcomes following systemic treatment and following surgery ([RNU) in each arm of the trial separately. (All patients) VII. To evaluate safety and tolerability of neoadjuvant aMVAC alone or in combination with durvalumab prior to RNU. (All patients)
OUTLINE: Patients eligible for cisplatin are randomized to Arms A or B. Patients ineligible for cisplatin are assigned to Arm C.
ARM A: Patients receive durvalumab intravenously (IV) over 60 minutes on day 1 of chemotherapy cycles 1 and 3. Patients also receive methotrexate IV over 2-3 minutes, vinblastine sulfate IV, doxorubicin IV, cisplatin IV over at least 2 hours on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery.
ARM B: Patients also receive methotrexate IV over 2-3 minutes, vinblastine sulfate IV, doxorubicin IV, cisplatin IV over at least 2 hours on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery.
ARM C: Patients receive durvalumab IV over 60 minutes on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery.
Patients also undergo tissue biopsy and blood sample collection on study, and computed tomography (CT) or magnetic resonance imaging (MRI) throughout the trial.
After completion of study treatment, patients are followed up within 30 days and then every 3-6 months for up to 5 years from study entry.
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 2
- Phase 3
Kontakte und Standorte
Studienorte
-
-
Arizona
-
Kingman, Arizona, Vereinigte Staaten, 86401
- Rekrutierung
- Kingman Regional Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 702-384-0013
- E-Mail: research@sncrf.org
-
Hauptermittler:
- Khawaja S. Jahangir
-
-
Arkansas
-
Fort Smith, Arkansas, Vereinigte Staaten, 72903
- Suspendiert
- Mercy Hospital Fort Smith
-
Little Rock, Arkansas, Vereinigte Staaten, 72205
- Aktiv, nicht rekrutierend
- University of Arkansas for Medical Sciences
-
-
California
-
Auburn, California, Vereinigte Staaten, 95602
- Aktiv, nicht rekrutierend
- Sutter Auburn Faith Hospital
-
Berkeley, California, Vereinigte Staaten, 94704
- Aktiv, nicht rekrutierend
- Alta Bates Summit Medical Center-Herrick Campus
-
Duarte, California, Vereinigte Staaten, 91010
- Aktiv, nicht rekrutierend
- City of Hope Comprehensive Cancer Center
-
Fremont, California, Vereinigte Staaten, 94538
- Aktiv, nicht rekrutierend
- Palo Alto Medical Foundation-Fremont
-
La Jolla, California, Vereinigte Staaten, 92093
- Rekrutierung
- UC San Diego Moores Cancer Center
-
Hauptermittler:
- Aditya Bagrodia
-
Kontakt:
- Site Public Contact
- Telefonnummer: 858-822-5354
- E-Mail: cancercto@ucsd.edu
-
Modesto, California, Vereinigte Staaten, 95355
- Aktiv, nicht rekrutierend
- Memorial Medical Center
-
Mountain View, California, Vereinigte Staaten, 94040
- Aktiv, nicht rekrutierend
- Palo Alto Medical Foundation-Camino Division
-
Palo Alto, California, Vereinigte Staaten, 94304
- Rekrutierung
- Stanford Cancer Institute Palo Alto
-
Hauptermittler:
- Ali R. Khaki
-
Kontakt:
- Site Public Contact
- Telefonnummer: 650-498-7061
- E-Mail: cancertrialsinfo@stanford.edu
-
Palo Alto, California, Vereinigte Staaten, 94301
- Aktiv, nicht rekrutierend
- Palo Alto Medical Foundation Health Care
-
Roseville, California, Vereinigte Staaten, 95661
- Aktiv, nicht rekrutierend
- Sutter Roseville Medical Center
-
Sacramento, California, Vereinigte Staaten, 95816
- Aktiv, nicht rekrutierend
- Sutter Medical Center Sacramento
-
San Diego, California, Vereinigte Staaten, 92103
- Rekrutierung
- UC San Diego Medical Center - Hillcrest
-
Hauptermittler:
- Aditya Bagrodia
-
Kontakt:
- Site Public Contact
- E-Mail: rhabbaba@health.ucsd.edu
-
San Francisco, California, Vereinigte Staaten, 94115
- Aktiv, nicht rekrutierend
- California Pacific Medical Center-Pacific Campus
-
Santa Cruz, California, Vereinigte Staaten, 95065
- Aktiv, nicht rekrutierend
- Palo Alto Medical Foundation-Santa Cruz
-
Santa Rosa, California, Vereinigte Staaten, 95403
- Aktiv, nicht rekrutierend
- Sutter Pacific Medical Foundation
-
Sunnyvale, California, Vereinigte Staaten, 94086
- Aktiv, nicht rekrutierend
- Palo Alto Medical Foundation-Sunnyvale
-
Vallejo, California, Vereinigte Staaten, 94589
- Aktiv, nicht rekrutierend
- Sutter Solano Medical Center/Cancer Center
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80045
- Rekrutierung
- UCHealth University of Colorado Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 720-848-0650
-
Hauptermittler:
- Elizabeth R. Kessler
-
Denver, Colorado, Vereinigte Staaten, 80206
- Suspendiert
- UCHealth - Cherry Creek
-
Fort Collins, Colorado, Vereinigte Staaten, 80524
- Rekrutierung
- Poudre Valley Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 970-297-6150
-
Hauptermittler:
- Elizabeth R. Kessler
-
Fort Collins, Colorado, Vereinigte Staaten, 80528
- Rekrutierung
- Cancer Care and Hematology-Fort Collins
-
Kontakt:
- Site Public Contact
- E-Mail: ecog.rss@jimmy.harvard.edu
-
Hauptermittler:
- Elizabeth R. Kessler
-
Greeley, Colorado, Vereinigte Staaten, 80631
- Rekrutierung
- UCHealth Greeley Hospital
-
Kontakt:
- Site Public Contact
- E-Mail: ecog.rss@jimmy.harvard.edu
-
Hauptermittler:
- Elizabeth R. Kessler
-
Highlands Ranch, Colorado, Vereinigte Staaten, 80129
- Rekrutierung
- UCHealth Highlands Ranch Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 720-848-0650
-
Hauptermittler:
- Elizabeth R. Kessler
-
Lone Tree, Colorado, Vereinigte Staaten, 80124
- Rekrutierung
- UCHealth Lone Tree Health Center
-
Kontakt:
- Site Public Contact
- E-Mail: ecog.rss@jimmy.harvard.edu
-
Hauptermittler:
- Elizabeth R. Kessler
-
Loveland, Colorado, Vereinigte Staaten, 80538
- Rekrutierung
- Medical Center of the Rockies
-
Kontakt:
- Site Public Contact
- Telefonnummer: 970-203-7083
-
Hauptermittler:
- Elizabeth R. Kessler
-
-
District of Columbia
-
Washington D.C., District of Columbia, Vereinigte Staaten, 20016
- Rekrutierung
- Sibley Memorial Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 202-243-2373
- E-Mail: jquiver1@jhmi.edu
-
Hauptermittler:
- Jean H. Hoffman-Censits
-
Washington D.C., District of Columbia, Vereinigte Staaten, 20010
- Rekrutierung
- MedStar Washington Hospital Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 202-877-8839
-
Hauptermittler:
- Suthee Rapisuwon
-
-
Florida
-
Jacksonville, Florida, Vereinigte Staaten, 32224-9980
- Aktiv, nicht rekrutierend
- Mayo Clinic in Florida
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30322
- Rekrutierung
- Emory University Hospital/Winship Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 404-778-1868
-
Hauptermittler:
- Jacqueline T. Brown
-
Atlanta, Georgia, Vereinigte Staaten, 30308
- Rekrutierung
- Emory University Hospital Midtown
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-946-7447
-
Hauptermittler:
- Jacqueline T. Brown
-
Atlanta, Georgia, Vereinigte Staaten, 30342
- Rekrutierung
- Emory Saint Joseph's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 404-851-7115
-
Hauptermittler:
- Jacqueline T. Brown
-
Decatur, Georgia, Vereinigte Staaten, 30033
- Rekrutierung
- Emory Decatur Hospital
-
Hauptermittler:
- Jacqueline T. Brown
-
Kontakt:
- Site Public Contact
- Telefonnummer: 440-778-1868
- E-Mail: clinicaltrialsoncology@dekalbmedical.org
-
-
Idaho
-
Nampa, Idaho, Vereinigte Staaten, 83687
- Rekrutierung
- Saint Alphonsus Cancer Care Center-Nampa
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Hauptermittler:
- Elie G. Dib
-
-
Illinois
-
Alton, Illinois, Vereinigte Staaten, 62002
- Suspendiert
- OSF Saint Anthony's Health Center
-
Barrington, Illinois, Vereinigte Staaten, 60010
- Rekrutierung
- Advocate Good Shepherd Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 847-842-4847
-
Hauptermittler:
- Thomas J. Saphner
-
Bloomington, Illinois, Vereinigte Staaten, 61704
- Aktiv, nicht rekrutierend
- Illinois CancerCare-Bloomington
-
Burr Ridge, Illinois, Vereinigte Staaten, 60527
- Aktiv, nicht rekrutierend
- Loyola Center for Health at Burr Ridge
-
Canton, Illinois, Vereinigte Staaten, 61520
- Aktiv, nicht rekrutierend
- Illinois CancerCare-Canton
-
Carbondale, Illinois, Vereinigte Staaten, 62902
- Suspendiert
- Memorial Hospital of Carbondale
-
Carterville, Illinois, Vereinigte Staaten, 62918
- Rekrutierung
- SIH Cancer Institute
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 618-985-3333
- E-Mail: clinical.research@sih.net
-
Carthage, Illinois, Vereinigte Staaten, 62321
- Aktiv, nicht rekrutierend
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Vereinigte Staaten, 62801
- Suspendiert
- Centralia Oncology Clinic
-
Chicago, Illinois, Vereinigte Staaten, 60657
- Rekrutierung
- Advocate Illinois Masonic Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 773-296-5360
-
Hauptermittler:
- Thomas J. Saphner
-
Crystal Lake, Illinois, Vereinigte Staaten, 60014
- Rekrutierung
- AMG Crystal Lake - Oncology
-
Kontakt:
- Site Public Contact
- Telefonnummer: 630-929-6129
- E-Mail: advocateresearch@advocate.com
-
Hauptermittler:
- Thomas J. Saphner
-
Danville, Illinois, Vereinigte Staaten, 61832
- Rekrutierung
- Carle at The Riverfront
-
Hauptermittler:
- Prem Sobti
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-Mail: Research@Carle.com
-
Decatur, Illinois, Vereinigte Staaten, 62526
- Rekrutierung
- Cancer Care Specialists of Illinois - Decatur
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-Mail: morganthaler.jodi@mhsil.com
-
Decatur, Illinois, Vereinigte Staaten, 62526
- Suspendiert
- Decatur Memorial Hospital
-
Dixon, Illinois, Vereinigte Staaten, 61021
- Aktiv, nicht rekrutierend
- Illinois CancerCare-Dixon
-
Downers Grove, Illinois, Vereinigte Staaten, 60515
- Rekrutierung
- Advocate Good Samaritan Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 630-275-1270
- E-Mail: Barbara.barhamand@advocatehealth.com
-
Hauptermittler:
- Thomas J. Saphner
-
Effingham, Illinois, Vereinigte Staaten, 62401
- Rekrutierung
- Carle Physician Group-Effingham
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-Mail: Research@carle.com
-
Hauptermittler:
- Prem Sobti
-
Effingham, Illinois, Vereinigte Staaten, 62401
- Rekrutierung
- Crossroads Cancer Center
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-Mail: morganthaler.jodi@mhsil.com
-
Elgin, Illinois, Vereinigte Staaten, 60123
- Rekrutierung
- Advocate Sherman Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 847-429-2907
-
Hauptermittler:
- Thomas J. Saphner
-
Eureka, Illinois, Vereinigte Staaten, 61530
- Aktiv, nicht rekrutierend
- Illinois CancerCare-Eureka
-
Galesburg, Illinois, Vereinigte Staaten, 61401
- Suspendiert
- Western Illinois Cancer Treatment Center
-
Galesburg, Illinois, Vereinigte Staaten, 61401
- Aktiv, nicht rekrutierend
- Illinois CancerCare-Galesburg
-
Hazel Crest, Illinois, Vereinigte Staaten, 60429
- Rekrutierung
- Advocate South Suburban Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 708-799-9995
-
Hauptermittler:
- Thomas J. Saphner
-
Homer Glen, Illinois, Vereinigte Staaten, 60491
- Aktiv, nicht rekrutierend
- Loyola Medicine Homer Glen
-
Kewanee, Illinois, Vereinigte Staaten, 61443
- Aktiv, nicht rekrutierend
- Illinois CancerCare-Kewanee Clinic
-
Libertyville, Illinois, Vereinigte Staaten, 60048
- Rekrutierung
- AMG Libertyville - Oncology
-
Kontakt:
- Site Public Contact
- Telefonnummer: 630-929-6129
- E-Mail: advocateresearch@advocatehealth.com
-
Hauptermittler:
- Thomas J. Saphner
-
Macomb, Illinois, Vereinigte Staaten, 61455
- Aktiv, nicht rekrutierend
- Illinois CancerCare-Macomb
-
Mattoon, Illinois, Vereinigte Staaten, 61938
- Rekrutierung
- Carle Physician Group-Mattoon/Charleston
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-Mail: Research@carle.com
-
Hauptermittler:
- Prem Sobti
-
Maywood, Illinois, Vereinigte Staaten, 60153
- Aktiv, nicht rekrutierend
- Loyola University Medical Center
-
Melrose Park, Illinois, Vereinigte Staaten, 60160
- Aktiv, nicht rekrutierend
- Marjorie Weinberg Cancer Center at Loyola-Gottlieb
-
Mount Vernon, Illinois, Vereinigte Staaten, 62864
- Rekrutierung
- SSM Health Good Samaritan
-
Hauptermittler:
- Jay W. Carlson
-
Kontakt:
- Site Public Contact
- Telefonnummer: 618-899-1894
- E-Mail: gayla.hall@ssmhealth.com
-
O'Fallon, Illinois, Vereinigte Staaten, 62269
- Rekrutierung
- Cancer Care Center of O'Fallon
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-Mail: morganthaler.jodi@mhsil.com
-
Oak Lawn, Illinois, Vereinigte Staaten, 60453-2699
- Rekrutierung
- Advocate Christ Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-323-8622
-
Hauptermittler:
- Thomas J. Saphner
-
Ottawa, Illinois, Vereinigte Staaten, 61350
- Aktiv, nicht rekrutierend
- Illinois CancerCare-Ottawa Clinic
-
Park Ridge, Illinois, Vereinigte Staaten, 60068
- Rekrutierung
- Advocate Lutheran General Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 847-384-3621
-
Hauptermittler:
- Thomas J. Saphner
-
Pekin, Illinois, Vereinigte Staaten, 61554
- Aktiv, nicht rekrutierend
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Vereinigte Staaten, 61636
- Suspendiert
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Vereinigte Staaten, 61615
- Aktiv, nicht rekrutierend
- Illinois CancerCare-Peoria
-
Peru, Illinois, Vereinigte Staaten, 61354
- Suspendiert
- Valley Radiation Oncology
-
Peru, Illinois, Vereinigte Staaten, 61354
- Aktiv, nicht rekrutierend
- Illinois CancerCare-Peru
-
Princeton, Illinois, Vereinigte Staaten, 61356
- Aktiv, nicht rekrutierend
- Illinois CancerCare-Princeton
-
Springfield, Illinois, Vereinigte Staaten, 62702
- Rekrutierung
- Southern Illinois University School of Medicine
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-545-7929
-
Springfield, Illinois, Vereinigte Staaten, 62702
- Rekrutierung
- Springfield Clinic
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-444-7541
-
Springfield, Illinois, Vereinigte Staaten, 62781
- Suspendiert
- Springfield Memorial Hospital
-
Urbana, Illinois, Vereinigte Staaten, 61801
- Rekrutierung
- Carle Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-Mail: Research@carle.com
-
Hauptermittler:
- Prem Sobti
-
Washington, Illinois, Vereinigte Staaten, 61571
- Aktiv, nicht rekrutierend
- Illinois CancerCare - Washington
-
-
Indiana
-
Richmond, Indiana, Vereinigte Staaten, 47374
- Aktiv, nicht rekrutierend
- Reid Health
-
-
Iowa
-
Ames, Iowa, Vereinigte Staaten, 50010
- Aktiv, nicht rekrutierend
- Mary Greeley Medical Center
-
Ames, Iowa, Vereinigte Staaten, 50010
- Aktiv, nicht rekrutierend
- McFarland Clinic - Ames
-
Bettendorf, Iowa, Vereinigte Staaten, 52722
- Rekrutierung
- University of Iowa Healthcare Cancer Services Quad Cities
-
Hauptermittler:
- Fernando Maciel Barbosa
-
Kontakt:
- Site Public Contact
- Telefonnummer: 563-355-7733
- E-Mail: katherine-daprile@uiowa.edu
-
Boone, Iowa, Vereinigte Staaten, 50036
- Aktiv, nicht rekrutierend
- McFarland Clinic - Boone
-
Fort Dodge, Iowa, Vereinigte Staaten, 50501
- Aktiv, nicht rekrutierend
- McFarland Clinic - Trinity Cancer Center
-
Iowa City, Iowa, Vereinigte Staaten, 52242
- Rekrutierung
- University of Iowa/Holden Comprehensive Cancer Center
-
Hauptermittler:
- Fernando Maciel Barbosa
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-237-1225
-
Jefferson, Iowa, Vereinigte Staaten, 50129
- Aktiv, nicht rekrutierend
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, Vereinigte Staaten, 50158
- Aktiv, nicht rekrutierend
- McFarland Clinic - Marshalltown
-
-
Kansas
-
Garden City, Kansas, Vereinigte Staaten, 67846
- Suspendiert
- Central Care Cancer Center - Garden City
-
Great Bend, Kansas, Vereinigte Staaten, 67530
- Suspendiert
- Central Care Cancer Center - Great Bend
-
-
Kentucky
-
Lexington, Kentucky, Vereinigte Staaten, 40536
- Rekrutierung
- University of Kentucky/Markey Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 859-257-3379
-
Hauptermittler:
- Patrick J. Hensley
-
-
Louisiana
-
Baton Rouge, Louisiana, Vereinigte Staaten, 70809
- Rekrutierung
- Mary Bird Perkins Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 225-215-1353
- E-Mail: clinicalresearch@marybird.com
-
Hauptermittler:
- Victor T. Lin
-
Metairie, Louisiana, Vereinigte Staaten, 70006
- Rekrutierung
- East Jefferson General Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 504-210-3539
- E-Mail: emede1@lsuhsc.edu
-
Hauptermittler:
- Rajasree P. Chowdry
-
Metairie, Louisiana, Vereinigte Staaten, 70006
- Rekrutierung
- LSU Healthcare Network / Metairie Multi-Specialty Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 504-210-3539
- E-Mail: emede1@lsuhsc.edu
-
Hauptermittler:
- Rajasree P. Chowdry
-
Metairie, Louisiana, Vereinigte Staaten, 70002
- Rekrutierung
- Mary Bird Perkins Cancer Center - Metairie
-
Hauptermittler:
- Victor T. Lin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 504-584-6990
-
New Orleans, Louisiana, Vereinigte Staaten, 70112
- Rekrutierung
- University Medical Center New Orleans
-
Kontakt:
- Site Public Contact
- Telefonnummer: 504-210-3539
- E-Mail: emede1@lsuhsc.edu
-
Hauptermittler:
- Rajasree P. Chowdry
-
-
Maine
-
Augusta, Maine, Vereinigte Staaten, 04330
- Rekrutierung
- Harold Alfond Center for Cancer Care
-
Kontakt:
- Site Public Contact
- Telefonnummer: 207-626-4855
-
Hauptermittler:
- Erin Adler
-
Biddeford, Maine, Vereinigte Staaten, 04005
- Suspendiert
- MaineHealth Maine Medical Center - Biddeford
-
Sanford, Maine, Vereinigte Staaten, 04073
- Rekrutierung
- MaineHealth Cancer Care Center of York County
-
Kontakt:
- Site Public Contact
- Telefonnummer: 207-459-1600
-
Hauptermittler:
- Erin Adler
-
Sanford, Maine, Vereinigte Staaten, 04073
- Rekrutierung
- MaineHealth Cancer Care and IV Therapy - Sanford
-
Kontakt:
- Site Public Contact
- Telefonnummer: 207-396-8670
- E-Mail: clinicalresearch@mainehealth.org
-
Hauptermittler:
- Erin Adler
-
Scarborough, Maine, Vereinigte Staaten, 04074
- Rekrutierung
- MaineHealth Maine Medical Center- Scarborough
-
Kontakt:
- Site Public Contact
- Telefonnummer: 207-396-8670
- E-Mail: clinicalresearch@mainehealth.org
-
Hauptermittler:
- Erin Adler
-
South Portland, Maine, Vereinigte Staaten, 04106
- Rekrutierung
- MaineHealth Cancer Care and IV Therapy - South Portland
-
Kontakt:
- Site Public Contact
- Telefonnummer: 207-396-8670
- E-Mail: clinicalresearch@mainehealth.org
-
Hauptermittler:
- Erin Adler
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21287
- Rekrutierung
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 410-955-8804
- E-Mail: jhcccro@jhmi.edu
-
Hauptermittler:
- Jean H. Hoffman-Censits
-
-
Massachusetts
-
Worcester, Massachusetts, Vereinigte Staaten, 01655
- Rekrutierung
- UMass Memorial Medical Center - University Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 508-856-3216
- E-Mail: cancer.research@umassmed.edu
-
Hauptermittler:
- Kriti Mittal
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48106
- Rekrutierung
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Elie G. Dib
-
Brighton, Michigan, Vereinigte Staaten, 48114
- Rekrutierung
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Elie G. Dib
-
Brighton, Michigan, Vereinigte Staaten, 48114
- Rekrutierung
- Trinity Health Medical Center - Brighton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Elie G. Dib
-
Canton, Michigan, Vereinigte Staaten, 48188
- Rekrutierung
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Elie G. Dib
-
Canton, Michigan, Vereinigte Staaten, 48188
- Rekrutierung
- Trinity Health Medical Center - Canton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Elie G. Dib
-
Chelsea, Michigan, Vereinigte Staaten, 48118
- Rekrutierung
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Elie G. Dib
-
Chelsea, Michigan, Vereinigte Staaten, 48118
- Rekrutierung
- Chelsea Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Elie G. Dib
-
Clarkston, Michigan, Vereinigte Staaten, 48346
- Rekrutierung
- Hematology Oncology Consultants-Clarkston
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Elie G. Dib
-
Clarkston, Michigan, Vereinigte Staaten, 48346
- Suspendiert
- Newland Medical Associates-Clarkston
-
Flint, Michigan, Vereinigte Staaten, 48503
- Rekrutierung
- Genesys Hurley Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 810-762-8038
- E-Mail: wstrong@ghci.org
-
Hauptermittler:
- Elie G. Dib
-
Flint, Michigan, Vereinigte Staaten, 48503
- Rekrutierung
- Hurley Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 810-762-8038
- E-Mail: wstrong@ghci.org
-
Hauptermittler:
- Elie G. Dib
-
Flint, Michigan, Vereinigte Staaten, 48503
- Suspendiert
- Genesee Hematology Oncology PC
-
Flint, Michigan, Vereinigte Staaten, 48503
- Rekrutierung
- Cancer Hematology Centers - Flint
-
Kontakt:
- Site Public Contact
- Telefonnummer: 810-762-8038
- E-Mail: wstrong@ghci.org
-
Hauptermittler:
- Elie G. Dib
-
Livonia, Michigan, Vereinigte Staaten, 48154
- Suspendiert
- Hope Cancer Clinic
-
Livonia, Michigan, Vereinigte Staaten, 48154
- Rekrutierung
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Elie G. Dib
-
Macomb, Michigan, Vereinigte Staaten, 48044
- Rekrutierung
- Henry Ford Saint John Hospital - Macomb Medical
-
Hauptermittler:
- Elie G. Dib
-
Kontakt:
- Site Public Contact
- Telefonnummer: 313-343-3166
- E-Mail: kforman1@hfhs.org
-
Pontiac, Michigan, Vereinigte Staaten, 48341
- Rekrutierung
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Elie G. Dib
-
Pontiac, Michigan, Vereinigte Staaten, 48341
- Rekrutierung
- Michigan Healthcare Professionals Pontiac
-
Hauptermittler:
- Elie G. Dib
-
Kontakt:
- Site Public Contact
- Telefonnummer: 248-858-6215
- E-Mail: Emily.Crofts@trinity-health.org
-
Pontiac, Michigan, Vereinigte Staaten, 48341
- Rekrutierung
- Trinity Health IHA Medical Group-Alice Gustafson Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Elie G. Dib
-
Saginaw, Michigan, Vereinigte Staaten, 48604
- Suspendiert
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Vereinigte Staaten, 48601
- Rekrutierung
- MyMichigan Medical Center Saginaw
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Elie G. Dib
-
Tawas City, Michigan, Vereinigte Staaten, 48764
- Rekrutierung
- MyMichigan Medical Center Tawas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Elie G. Dib
-
West Branch, Michigan, Vereinigte Staaten, 48661
- Suspendiert
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Ypsilanti, Michigan, Vereinigte Staaten, 48106
- Rekrutierung
- Huron Gastroenterology PC
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Elie G. Dib
-
Ypsilanti, Michigan, Vereinigte Staaten, 48197
- Rekrutierung
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Elie G. Dib
-
-
Minnesota
-
Burnsville, Minnesota, Vereinigte Staaten, 55337
- Suspendiert
- Fairview Ridges Hospital
-
Burnsville, Minnesota, Vereinigte Staaten, 55337
- Suspendiert
- Minnesota Oncology - Burnsville
-
Cambridge, Minnesota, Vereinigte Staaten, 55008
- Suspendiert
- Cambridge Medical Center
-
Coon Rapids, Minnesota, Vereinigte Staaten, 55433
- Rekrutierung
- Mercy Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Edina, Minnesota, Vereinigte Staaten, 55435
- Suspendiert
- Fairview Southdale Hospital
-
Edina, Minnesota, Vereinigte Staaten, 55435
- Rekrutierung
- Minnesota Oncology - Edina
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Fridley, Minnesota, Vereinigte Staaten, 55432
- Aktiv, nicht rekrutierend
- Unity Hospital
-
Maple Grove, Minnesota, Vereinigte Staaten, 55369
- Suspendiert
- Fairview Clinics and Surgery Center Maple Grove
-
Maplewood, Minnesota, Vereinigte Staaten, 55109
- Rekrutierung
- Minnesota Oncology Hematology PA-Maplewood
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Maplewood, Minnesota, Vereinigte Staaten, 55109
- Suspendiert
- Saint John's Hospital - Healtheast
-
Minneapolis, Minnesota, Vereinigte Staaten, 55407
- Suspendiert
- Abbott-Northwestern Hospital
-
Minneapolis, Minnesota, Vereinigte Staaten, 55415
- Suspendiert
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Vereinigte Staaten, 55454
- Suspendiert
- Health Partners Inc
-
Monticello, Minnesota, Vereinigte Staaten, 55362
- Suspendiert
- Monticello Cancer Center
-
New Ulm, Minnesota, Vereinigte Staaten, 56073
- Suspendiert
- New Ulm Medical Center
-
Princeton, Minnesota, Vereinigte Staaten, 55371
- Suspendiert
- Fairview Northland Medical Center
-
Robbinsdale, Minnesota, Vereinigte Staaten, 55422
- Suspendiert
- North Memorial Medical Health Center
-
Rochester, Minnesota, Vereinigte Staaten, 55905
- Rekrutierung
- Mayo Clinic in Rochester
-
Kontakt:
- Site Public Contact
- Telefonnummer: 855-776-0015
-
Hauptermittler:
- Lance C. Pagliaro
-
Saint Louis Park, Minnesota, Vereinigte Staaten, 55416
- Rekrutierung
- Park Nicollet Clinic - Saint Louis Park
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Saint Paul, Minnesota, Vereinigte Staaten, 55101
- Rekrutierung
- Regions Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Saint Paul, Minnesota, Vereinigte Staaten, 55102
- Suspendiert
- United Hospital
-
Shakopee, Minnesota, Vereinigte Staaten, 55379
- Suspendiert
- Saint Francis Regional Medical Center
-
Stillwater, Minnesota, Vereinigte Staaten, 55082
- Rekrutierung
- Lakeview Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Waconia, Minnesota, Vereinigte Staaten, 55387
- Suspendiert
- Ridgeview Medical Center
-
Willmar, Minnesota, Vereinigte Staaten, 56201
- Suspendiert
- Rice Memorial Hospital
-
Woodbury, Minnesota, Vereinigte Staaten, 55125
- Rekrutierung
- Minnesota Oncology Hematology PA-Woodbury
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Wyoming, Minnesota, Vereinigte Staaten, 55092
- Suspendiert
- Fairview Lakes Medical Center
-
-
Missouri
-
Ballwin, Missouri, Vereinigte Staaten, 63011
- Suspendiert
- Mercy Oncology and Hematology - Clayton-Clarkson
-
Bolivar, Missouri, Vereinigte Staaten, 65613
- Suspendiert
- Central Care Cancer Center - Bolivar
-
Cape Girardeau, Missouri, Vereinigte Staaten, 63703
- Rekrutierung
- Saint Francis Medical Center
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 573-334-2230
- E-Mail: sfmc@sfmc.net
-
Cape Girardeau, Missouri, Vereinigte Staaten, 63703
- Suspendiert
- Mercy Cancer Center - Cape Girardeau
-
Farmington, Missouri, Vereinigte Staaten, 63640
- Rekrutierung
- Parkland Health Center - Farmington
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
Jefferson City, Missouri, Vereinigte Staaten, 65109
- Suspendiert
- MU Health Care Goldschmidt Cancer Center
-
Joplin, Missouri, Vereinigte Staaten, 64804
- Suspendiert
- Freeman Health System
-
Joplin, Missouri, Vereinigte Staaten, 64804
- Suspendiert
- Mercy Hospital Joplin
-
Rolla, Missouri, Vereinigte Staaten, 65401
- Suspendiert
- Mercy Clinic-Rolla-Cancer and Hematology
-
Rolla, Missouri, Vereinigte Staaten, 65401
- Suspendiert
- Phelps Health Delbert Day Cancer Institute
-
Saint Joseph, Missouri, Vereinigte Staaten, 64506
- Suspendiert
- Heartland Regional Medical Center
-
Sainte Genevieve, Missouri, Vereinigte Staaten, 63670
- Rekrutierung
- Sainte Genevieve County Memorial Hospital
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
Springfield, Missouri, Vereinigte Staaten, 65804
- Suspendiert
- Mercy Hospital Springfield
-
Springfield, Missouri, Vereinigte Staaten, 65807
- Suspendiert
- CoxHealth South Hospital
-
St Louis, Missouri, Vereinigte Staaten, 63128
- Rekrutierung
- Mercy Hospital South
-
Hauptermittler:
- Jay W. Carlson
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-525-6042
- E-Mail: Danielle.Werle@mercy.net
-
St Louis, Missouri, Vereinigte Staaten, 63141
- Rekrutierung
- Mercy Hospital Saint Louis
-
Hauptermittler:
- Jay W. Carlson
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-251-7066
-
St Louis, Missouri, Vereinigte Staaten, 63109
- Suspendiert
- Mercy Infusion Center - Chippewa
-
St Louis, Missouri, Vereinigte Staaten, 63131
- Rekrutierung
- Missouri Baptist Medical Center
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
Sullivan, Missouri, Vereinigte Staaten, 63080
- Rekrutierung
- Missouri Baptist Sullivan Hospital
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
Washington, Missouri, Vereinigte Staaten, 63090
- Suspendiert
- Mercy Hospital Washington
-
-
Nevada
-
Las Vegas, Nevada, Vereinigte Staaten, 89102
- Suspendiert
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Vereinigte Staaten, 89183
- Suspendiert
- OptumCare Cancer Care at Fort Apache
-
-
New Jersey
-
Hackensack, New Jersey, Vereinigte Staaten, 07601
- Abgeschlossen
- Hackensack University Medical Center
-
Livingston, New Jersey, Vereinigte Staaten, 07039
- Rekrutierung
- Cooperman Barnabas Medical Center
-
Hauptermittler:
- Saum B. Ghodoussipour
-
Kontakt:
- Site Public Contact
- Telefonnummer: 973-322-5200
-
New Brunswick, New Jersey, Vereinigte Staaten, 08903
- Rekrutierung
- Rutgers Cancer Institute of New Jersey
-
Hauptermittler:
- Saum B. Ghodoussipour
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-235-7356
-
Toms River, New Jersey, Vereinigte Staaten, 08755
- Rekrutierung
- Community Medical Center
-
Hauptermittler:
- Saum B. Ghodoussipour
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-557-8294
- E-Mail: Lennette.Gonzales@rwjbh.org
-
-
New Mexico
-
Albuquerque, New Mexico, Vereinigte Staaten, 87106
- Rekrutierung
- University of New Mexico Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 505-925-0348
- E-Mail: HSC-ClinicalTrialInfo@salud.unm.edu
-
Hauptermittler:
- Amy C. Tarnower
-
-
New York
-
Buffalo, New York, Vereinigte Staaten, 14263
- Aktiv, nicht rekrutierend
- Roswell Park Cancer Institute
-
-
North Carolina
-
Clinton, North Carolina, Vereinigte Staaten, 28328
- Rekrutierung
- Southeastern Medical Oncology Center-Clinton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 919-587-9084
- E-Mail: jfields@cancersmoc.com
-
Hauptermittler:
- Samer S. Kasbari
-
Goldsboro, North Carolina, Vereinigte Staaten, 27534
- Rekrutierung
- Southeastern Medical Oncology Center-Goldsboro
-
Kontakt:
- Site Public Contact
- Telefonnummer: 919-587-9084
- E-Mail: jfields@cancersmoc.com
-
Hauptermittler:
- Samer S. Kasbari
-
Jacksonville, North Carolina, Vereinigte Staaten, 28546
- Rekrutierung
- Southeastern Medical Oncology Center-Jacksonville
-
Hauptermittler:
- Samer S. Kasbari
-
Kontakt:
- Site Public Contact
- Telefonnummer: 910-587-9084
- E-Mail: jfields@cancersmoc.com
-
Winston-Salem, North Carolina, Vereinigte Staaten, 27157
- Aktiv, nicht rekrutierend
- Wake Forest University Health Sciences
-
-
Ohio
-
Centerville, Ohio, Vereinigte Staaten, 45459
- Rekrutierung
- Miami Valley Hospital South
-
Kontakt:
- Site Public Contact
- Telefonnummer: 937-528-2900
- E-Mail: clinical.trials@daytonncorp.org
-
Hauptermittler:
- Tarek M. Sabagh
-
Centerville, Ohio, Vereinigte Staaten, 45459
- Aktiv, nicht rekrutierend
- Dayton Physicians LLC-Miami Valley South
-
Dayton, Ohio, Vereinigte Staaten, 45409
- Rekrutierung
- Miami Valley Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 937-528-2900
- E-Mail: clinical.trials@daytonncorp.org
-
Hauptermittler:
- Tarek M. Sabagh
-
Dayton, Ohio, Vereinigte Staaten, 45415
- Rekrutierung
- Miami Valley Hospital North
-
Kontakt:
- Site Public Contact
- Telefonnummer: 937-528-2900
- E-Mail: clinical.trials@daytonncorp.org
-
Hauptermittler:
- Tarek M. Sabagh
-
Dayton, Ohio, Vereinigte Staaten, 45409
- Rekrutierung
- Premier Blood and Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 937-276-8320
-
Hauptermittler:
- Tarek M. Sabagh
-
Dayton, Ohio, Vereinigte Staaten, 45415
- Aktiv, nicht rekrutierend
- Dayton Physician LLC - Englewood
-
Findlay, Ohio, Vereinigte Staaten, 45840
- Aktiv, nicht rekrutierend
- Armes Family Cancer Center
-
Franklin, Ohio, Vereinigte Staaten, 45005-1066
- Rekrutierung
- Atrium Medical Center-Middletown Regional Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 937-528-2900
- E-Mail: clinical.trials@daytonncorp.org
-
Hauptermittler:
- Tarek M. Sabagh
-
Franklin, Ohio, Vereinigte Staaten, 45005
- Aktiv, nicht rekrutierend
- Dayton Physicians LLC-Atrium
-
Greenville, Ohio, Vereinigte Staaten, 45331
- Rekrutierung
- Miami Valley Cancer Care and Infusion
-
Hauptermittler:
- Tarek M. Sabagh
-
Kontakt:
- Site Public Contact
- Telefonnummer: 937-569-7515
-
Kettering, Ohio, Vereinigte Staaten, 45409
- Aktiv, nicht rekrutierend
- Greater Dayton Cancer Center
-
Kettering, Ohio, Vereinigte Staaten, 45429
- Aktiv, nicht rekrutierend
- Kettering Medical Center
-
Springfield, Ohio, Vereinigte Staaten, 45504
- Suspendiert
- Springfield Regional Cancer Center
-
Sylvania, Ohio, Vereinigte Staaten, 43560
- Rekrutierung
- ProMedica Flower Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 419-824-1842
- E-Mail: PCIOncResearch@promedica.org
-
Hauptermittler:
- Jeffrey H. Muler
-
Troy, Ohio, Vereinigte Staaten, 45373
- Rekrutierung
- Upper Valley Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 937-528-2900
- E-Mail: clinical.trials@daytonncorp.org
-
Hauptermittler:
- Tarek M. Sabagh
-
-
Oklahoma
-
Lawton, Oklahoma, Vereinigte Staaten, 73505
- Rekrutierung
- Cancer Centers of Southwest Oklahoma Research
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-231-4440
-
Hauptermittler:
- Adanma Anji Ayanambakkam Attanathi
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
- Rekrutierung
- University of Oklahoma Health Sciences Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 405-271-8777
- E-Mail: ou-clinical-trials@ouhsc.edu
-
Hauptermittler:
- Adanma Anji Ayanambakkam Attanathi
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73120
- Suspendiert
- Mercy Hospital Oklahoma City
-
-
Pennsylvania
-
Erie, Pennsylvania, Vereinigte Staaten, 16505
- Rekrutierung
- UPMC Hillman Cancer Center Erie
-
Hauptermittler:
- Leonard J. Appleman
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-864-7716
- E-Mail: ClinicalResearchServices@upmc.edu
-
Greensburg, Pennsylvania, Vereinigte Staaten, 15601
- Rekrutierung
- UPMC Cancer Centers - Arnold Palmer Pavilion
-
Kontakt:
- Site Public Contact
- Telefonnummer: 724-838-1900
-
Hauptermittler:
- Leonard J. Appleman
-
Hershey, Pennsylvania, Vereinigte Staaten, 17033-0850
- Rekrutierung
- Penn State Milton S Hershey Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 717-531-3779
- E-Mail: CTO@hmc.psu.edu
-
Hauptermittler:
- Monika Joshi
-
Monroeville, Pennsylvania, Vereinigte Staaten, 15146
- Rekrutierung
- UPMC Hillman Cancer Center - Monroeville
-
Hauptermittler:
- Leonard J. Appleman
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-864-7716
- E-Mail: ClinicalResearchServices@upmc.edu
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19107
- Rekrutierung
- Thomas Jefferson University Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 215-600-9151
- E-Mail: ONCTrialNow@jefferson.edu
-
Hauptermittler:
- William J. Tester
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
- Rekrutierung
- University of Pennsylvania/Abramson Cancer Center
-
Hauptermittler:
- Ronac Mamtani
-
Kontakt:
- Site Public Contact
- Telefonnummer: 215-349-8245
- E-Mail: PMCancerResearch@pennmedicine.upenn.edu
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15237
- Rekrutierung
- UPMC-Passavant Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-367-6454
-
Hauptermittler:
- Leonard J. Appleman
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15243
- Rekrutierung
- UPMC-Saint Clair Hospital Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-502-3920
-
Hauptermittler:
- Leonard J. Appleman
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15232
- Rekrutierung
- UPMC Hillman Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-647-8073
-
Hauptermittler:
- Leonard J. Appleman
-
Washington, Pennsylvania, Vereinigte Staaten, 15301
- Rekrutierung
- UPMC Cancer Center-Washington
-
Kontakt:
- Site Public Contact
- E-Mail: ecog.rss@jimmy.harvard.edu
-
Hauptermittler:
- Leonard J. Appleman
-
West Reading, Pennsylvania, Vereinigte Staaten, 19611
- Rekrutierung
- Reading Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 610-988-9323
-
Hauptermittler:
- Terrence P. Cescon
-
-
South Carolina
-
Charleston, South Carolina, Vereinigte Staaten, 29425
- Aktiv, nicht rekrutierend
- Medical University of South Carolina
-
-
Texas
-
Dallas, Texas, Vereinigte Staaten, 75390
- Rekrutierung
- UT Southwestern/Simmons Cancer Center-Dallas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 214-648-7097
- E-Mail: canceranswerline@UTSouthwestern.edu
-
Hauptermittler:
- Vitaly Margulis
-
Dallas, Texas, Vereinigte Staaten, 75235
- Rekrutierung
- Parkland Memorial Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 214-590-5582
- E-Mail: canceranswerline@UTSouthwestern.edu
-
Hauptermittler:
- Vitaly Margulis
-
Dallas, Texas, Vereinigte Staaten, 75237
- Suspendiert
- UT Southwestern Simmons Cancer Center - RedBird
-
Fort Worth, Texas, Vereinigte Staaten, 76104
- Rekrutierung
- UT Southwestern/Simmons Cancer Center-Fort Worth
-
Kontakt:
- Site Public Contact
- Telefonnummer: 214-648-7097
- E-Mail: canceranswerline@UTSouthwestern.edu
-
Hauptermittler:
- Vitaly Margulis
-
Richardson, Texas, Vereinigte Staaten, 75080
- Rekrutierung
- UT Southwestern Clinical Center at Richardson/Plano
-
Kontakt:
- Site Public Contact
- Telefonnummer: 972-669-7044
- E-Mail: Suzanne.cole@utsouthwestern.edu
-
Hauptermittler:
- Vitaly Margulis
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98195
- Rekrutierung
- University of Washington Medical Center - Montlake
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-804-8824
-
Hauptermittler:
- Petros Grivas
-
Seattle, Washington, Vereinigte Staaten, 98109
- Rekrutierung
- Fred Hutchinson Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-804-8824
-
Hauptermittler:
- Petros Grivas
-
-
West Virginia
-
Charleston, West Virginia, Vereinigte Staaten, 25304
- Rekrutierung
- Vandalia Health/CAMC Institute for Academic Medicine
-
Hauptermittler:
- Kok Hoe Chan
-
Kontakt:
- Site Public Contact
- Telefonnummer: 304-388-9944
- E-Mail: CAMCClinicalTrials@vandaliahealth.org
-
-
Wisconsin
-
Appleton, Wisconsin, Vereinigte Staaten, 54911
- Rekrutierung
- ThedaCare Regional Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 920-364-3604
- E-Mail: ResearchDept@thedacare.org
-
Hauptermittler:
- Matthias Weiss
-
Burlington, Wisconsin, Vereinigte Staaten, 53105
- Rekrutierung
- Aurora Cancer Care-Southern Lakes VLCC
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Thomas J. Saphner
-
Eau Claire, Wisconsin, Vereinigte Staaten, 54701
- Rekrutierung
- Marshfield Medical Center-EC Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-Mail: oncology.clinical.trials@marshfieldresearch.org
-
Hauptermittler:
- Seth O. Fagbemi
-
Germantown, Wisconsin, Vereinigte Staaten, 53022
- Rekrutierung
- Aurora Health Care Germantown Health Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Thomas J. Saphner
-
Grafton, Wisconsin, Vereinigte Staaten, 53024
- Rekrutierung
- Aurora Cancer Care-Grafton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Thomas J. Saphner
-
Green Bay, Wisconsin, Vereinigte Staaten, 54311
- Rekrutierung
- Aurora BayCare Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Thomas J. Saphner
-
Kenosha, Wisconsin, Vereinigte Staaten, 53142
- Rekrutierung
- Aurora Cancer Care-Kenosha South
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Thomas J. Saphner
-
Marinette, Wisconsin, Vereinigte Staaten, 54143
- Rekrutierung
- Aurora Bay Area Medical Group-Marinette
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Thomas J. Saphner
-
Marshfield, Wisconsin, Vereinigte Staaten, 54449
- Rekrutierung
- Marshfield Medical Center-Marshfield
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-Mail: oncology.clinical.trials@marshfieldresearch.org
-
Hauptermittler:
- Seth O. Fagbemi
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53209
- Rekrutierung
- Aurora Cancer Care-Milwaukee
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Thomas J. Saphner
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53215
- Rekrutierung
- Aurora Saint Luke's Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Thomas J. Saphner
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53233
- Rekrutierung
- Aurora Sinai Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Thomas J. Saphner
-
Minocqua, Wisconsin, Vereinigte Staaten, 54548
- Rekrutierung
- Marshfield Medical Center - Minocqua
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-Mail: oncology.clinical.trials@marshfieldresearch.org
-
Hauptermittler:
- Seth O. Fagbemi
-
Mukwonago, Wisconsin, Vereinigte Staaten, 53149
- Rekrutierung
- ProHealth D N Greenwald Center
-
Kontakt:
- Site Public Contact
- E-Mail: research.institute@phci.org
-
Hauptermittler:
- Timothy R. Wassenaar
-
New Richmond, Wisconsin, Vereinigte Staaten, 54017
- Suspendiert
- Cancer Center of Western Wisconsin
-
Oconomowoc, Wisconsin, Vereinigte Staaten, 53066
- Rekrutierung
- ProHealth Oconomowoc Memorial Hospital
-
Hauptermittler:
- Timothy R. Wassenaar
-
Kontakt:
- Site Public Contact
- Telefonnummer: 262-928-7878
-
Oshkosh, Wisconsin, Vereinigte Staaten, 54904
- Rekrutierung
- Vince Lombardi Cancer Clinic - Oshkosh
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Thomas J. Saphner
-
Racine, Wisconsin, Vereinigte Staaten, 53406
- Rekrutierung
- Aurora Cancer Care-Racine
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Thomas J. Saphner
-
Rice Lake, Wisconsin, Vereinigte Staaten, 54868
- Rekrutierung
- Marshfield Medical Center-Rice Lake
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-Mail: oncology.clinical.trials@marshfieldresearch.org
-
Hauptermittler:
- Seth O. Fagbemi
-
Sheboygan, Wisconsin, Vereinigte Staaten, 53081
- Rekrutierung
- Vince Lombardi Cancer Clinic-Sheboygan
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Thomas J. Saphner
-
Stevens Point, Wisconsin, Vereinigte Staaten, 54482
- Rekrutierung
- Marshfield Medical Center-River Region at Stevens Point
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-Mail: oncology.clinical.trials@marshfieldresearch.org
-
Hauptermittler:
- Seth O. Fagbemi
-
Summit, Wisconsin, Vereinigte Staaten, 53066
- Rekrutierung
- Aurora Medical Center in Summit
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Thomas J. Saphner
-
Two Rivers, Wisconsin, Vereinigte Staaten, 54241
- Rekrutierung
- Vince Lombardi Cancer Clinic-Two Rivers
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Thomas J. Saphner
-
Waukesha, Wisconsin, Vereinigte Staaten, 53188
- Rekrutierung
- ProHealth Waukesha Memorial Hospital
-
Hauptermittler:
- Timothy R. Wassenaar
-
Kontakt:
- Site Public Contact
- Telefonnummer: 262-928-7632
-
Waukesha, Wisconsin, Vereinigte Staaten, 53188
- Rekrutierung
- UW Cancer Center at ProHealth Care
-
Hauptermittler:
- Timothy R. Wassenaar
-
Kontakt:
- Site Public Contact
- Telefonnummer: 262-928-5539
- E-Mail: Chanda.miller@phci.org
-
Waupaca, Wisconsin, Vereinigte Staaten, 54981
- Rekrutierung
- ThedaCare Cancer Care - Waupaca
-
Kontakt:
- Site Public Contact
- Telefonnummer: 920-364-3605
- E-Mail: ResearchDept@thedacare.org
-
Hauptermittler:
- Matthias Weiss
-
Wauwatosa, Wisconsin, Vereinigte Staaten, 53226
- Rekrutierung
- Aurora Cancer Care-Milwaukee West
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Thomas J. Saphner
-
West Allis, Wisconsin, Vereinigte Staaten, 53227
- Rekrutierung
- Aurora West Allis Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Thomas J. Saphner
-
Weston, Wisconsin, Vereinigte Staaten, 54476
- Rekrutierung
- Marshfield Medical Center - Weston
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-Mail: oncology.clinical.trials@marshfieldresearch.org
-
Hauptermittler:
- Seth O. Fagbemi
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
STEP 1 REGISTRATION AND RANDOMIZATION
-
Patients must be >= 18 years of age
-
Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
-
Patient must have a diagnosis of high grade upper tract urothelial carcinoma expected within 14 weeks (98 days) prior to registration/randomization with one of the following:
-
Biopsy (gold standard, preferred) and either upper urinary tract mass on cross-sectional imaging or tumor directly visualized during upper urinary tract endoscopy
-
High grade cytology and clinically estimated invasive upper urinary tract mass on cross-sectional imaging (e.g., including presence of tumor-related hydronephrosis) or tumor directly visualized during upper urinary tract endoscopy
-
NOTE: Universal histologic testing of UTUC with additional studies, such as immunohistochemistry and/or microsatellite instability, is strongly recommended to identify patients with high probability of Lynch-related or other germline mutation related cancers whom clinicians should refer for genetic counseling and germline testing (this is not required for eligibility)
- Due to the anatomy of upper urinary tract and lack of muscularis propria, pathologic evidence of cT2 on biopsy is usually not possible
-
-
-
Patients must not have any component of small cell/neuroendocrine carcinoma. Other histologic subtypes (variants) are permitted provided the half or predominant (>= 50%) subtype is conventional urothelial carcinoma
-
Leukocytes >= 3,000/mcL (obtained =< 14 days prior to registration/randomization)
-
Platelets >= 100,000/mcL (obtained =< 14 days prior to registration/randomization)
-
Total bilirubin =< 1.2 mg/dL (or ≤ 2 mg/dL for patients with Gilbert's disease)
-
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2 x institutional ULN (obtained =< 14 days prior to registration/randomization)
-
Hemoglobin (Hgb) >= 9 g/dL (obtained =< 14 days prior to registration/randomization)
- NOTE: Packed red blood transfusion is allowed to achieve this parameter as per treating investigator
-
Patients must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy. A patient of childbearing potential is defined as any patient, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
-
Patients of childbearing potential and sexually active patients must not expect to conceive or father children, either by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse from the time of registration, while on study treatment and for at least 6 months after the last dose of protocol treatment
-
Patients must have no evidence of metastatic disease or clinically enlarged regional lymph nodes (>= 1.5 cm short axis) on imaging required within 28 days prior to registration (Non-regional findings >=1.5 cm short axis that in the opinion of the investigator are not concerning for involvement based on radiographic characteristics, chronicity, avidity on positron emission tomography (PET) scan or other imaging or other criteria can be eligible based on investigator discretion).
- NOTE: Patients with elevated alkaline phosphatase, calcium or suspicious bone pain/tenderness can also undergo baseline bone scan to evaluate for bone metastasis at the discretion of local provider.
-
Patient must meet below criteria for prior/current malignancy history:
-
Non-urothelial cancer malignancy history:
-
Patient must not have another active (or within two years) second malignancy other than resected non-melanoma skin cancers, resected in situ breast, cervical or other in situ carcinoma, and either clinically insignificant per the investigator (e.g. =< Gleason 3+4) on active surveillance (or watchful waiting) or previously treated prostate cancer with no rising prostate specific antigen (PSA) and no plan to treat
- NOTE: Patients with prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
-
Urothelial cancer malignancy history:
- Patient may have a history of resectable urothelial cancer as long as patients meet one of the following:
- T0, Ta or Tis at any time
- T1-4a N0 and no evidence of disease (NED) for more than 2 years from the latest therapy [e.g., radical surgery, transurethral resection of bladder tumor (TURBT), radiation, chemotherapy (neoadjuvant or adjuvant, or with radiation)]. Prior systemic immune checkpoint inhibitor is not allowed.
- Patient with history of >= pT4b, N+, and/or M1 UC is not eligible.
- NOTE: Patients in whom concomitant or prior bladder/urethra predominant (>= 50%) urothelial carcinoma have been surgically resected and demonstrated to be only Ta or carcinoma in situ (CIS) (< cT1 N0) are eligible regardless of time elapsed
-
-
-
Patient must not have any uncontrolled illness including, but not limited to, ongoing or active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice), symptomatic congestive heart failure (CHF), myocardial infarction (MI) or unstable angina pectoris, significant uncontrolled cardiac arrhythmia, clinically relevant liver cirrhosis, interstitial lung disease, or psychiatric illness/social situations in the three months prior to registration that would limit compliance with study requirements
-
Patient must not have received prior radiation therapy to >= 25% of the bone marrow for other diseases
-
Patient must not have received prior systemic anthracycline therapy
- NOTE: Patients who have received prior intravesical therapy at any time for non-muscle invasive urothelial carcinoma of the bladder are eligible
-
Patient must not have either history of or active autoimmune disease requiring immunosuppressive therapy within 2 years prior to registration/randomization or any history of inflammatory bowel disease (inflammatory bowel disease [IBD], e.g. ulcerative colitis, or Crohn's disease), neuromuscular autoimmune condition, immune-related pneumonitis or interstitial lung disease. Patients with well-controlled hyper/hypothyroidism, celiac controlled by diet alone, diabetes mellitus type I, vitiligo, alopecia, psoriasis, eczema, lichen planus, or similar skin/mucosa condition are eligible
-
Patient must not be on or have used immunosuppressive medication within 14 days prior to the first dose of durvalumab. The following are exceptions to this criterion and are allowed:
- Intranasal, inhaled, intra-auricular, topical steroids, or local steroid injections (e.g. intra-articular injection
- Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent at the time of enrollment
- Steroids as pre-medications for hypersensitivity reactions (e.g. computed tomography [CT] pre-medication)
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration/randomization are eligible for this trial
- NOTE: These patients must be stable on their anti-retroviral regimen with evidence of at least two undetectable viral loads within the past 6 months on the same regimen; the most recent undetectable viral load must be within the past 12 weeks. They must have a CD4 count of greater than 250 cells/mcL over the past 6 months on this same anti-retroviral regimen and must not have had a CD4 count < 200 cells/mcL over the past 2 years, unless it was deemed related to the cancer and/or chemotherapy induced bone marrow suppression. They must not be currently receiving prophylactic therapy for an opportunistic infection and must not have had an opportunistic infection within the past 6 months
- NOTE: For patients who have received chemotherapy in the past 6 months, a CD4 count < 250 cells/mcL during chemotherapy is permitted as long as viral loads were undetectable during this same chemotherapy. They must have an undetectable viral load and a CD4 count >= 250 cells/mcL within 7 days of registration/randomization
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- NOTE: Testing for HIV, hepatitis B or hepatitis C is not required unless clinically indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and have undetectable viral load. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
-
Patient must not have received live attenuated vaccine within 30 days prior to the first dose of durvalumab, while on protocol treatment and within 30 days after the last dose of durvalumab
-
Patient must not have had a major surgical procedure within 28 days prior to registration/randomization
- NOTE: Cystoscopy/ureteroscopy/TURBT, stent placement or nephrostomy tube is not considered major surgery
-
Patient must not have history of allogenic organ transplantation
-
Patient must have a body weight of > 30 kg
-
Patient must have life expectancy of >= 12 weeks
-
Patient must have creatinine clearance > 15 ml/min as estimated by Cockcroft-Gault formula or glomerular filtration rate (GFR) > 15 ml/min/1.73m^2 within 28 days prior to registration/randomization
-
NOTE: Patients will be assigned to cisplatin-ineligible and cisplatin-eligible cohorts based on their creatinine clearance, Eastern Cooperative Oncology Group (ECOG) performance status, and grade (if any) of peripheral neuropathy and/or hearing loss in keeping with recommended cisplatin contraindications. Patients who are cisplatin-eligible will be randomized to either Arm A or Arm B and patients who are cisplatin-ineligible will be registered to Arm C
-
Patients that meet any of the following four criteria will be registered to the cisplatin-ineligible Arm C if they meet other eligibility criteria:
- Creatinine clearance > 15 ml/min and =< 50 ml/min (estimated by Cockcroft-Gault formula) or GFR > 15ml/min/1.73m^2 and ≤ 50 ml/min/1.73 m^2
- Hearing loss >= 3
- Neuropathy >= 2
- ECOG performance status 2
-
In addition, the patient must have an absolute neutrophil count (ANC) >= 1,000/mcL obtained =< 14 days prior to registration
-
Patients that meet all of the following four criteria will be randomized to the cisplatin-eligible Arm A or Arm B:
- Creatinine clearance > 50ml/min (estimated by Cockcroft-Gault formula) or GFR > 50ml/min/1.73m^2
- ECOG performance status 0-1
- Hearing loss grade 0-2
- Neuropathy 0-1
-
In addition, the patient must have an absolute neutrophil count (ANC) >= 1,500/mcL obtained =< 14 days prior to randomization
-
Also, the patient must have left ventricular ejection fraction (LVEF) >= 50% by (either multigated acquisition scan [MUGA] or 2-D echocardiogram) obtained within obtained within 28 days prior to randomization
-
-
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Arm A (durvalumab, chemotherapy)
Patients receive durvalumab IV over 60 minutes on day 1 of chemotherapy cycles 1 and 3. Patients also receive methotrexate IV over 2-3 minutes, vinblastine sulfate IV, doxorubicin IV, cisplatin IV over at least 2 hours on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery. Patients also undergo tissue biopsy and blood sample collection on study, and CT or MRI throughout the trial. |
Given IV
Andere Namen:
Undergo blood sample collection
Andere Namen:
Given IV
Andere Namen:
Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Undergo surgery Undergo tissue biopsy
Andere Namen:
Given IV
Andere Namen:
Given Iv
Andere Namen:
Given via injection
Andere Namen:
Given Iv
Andere Namen:
|
|
Aktiver Komparator: Arm B (chemotherapy)
Patients also receive methotrexate IV over 2-3 minutes, vinblastine sulfate IV, doxorubicin IV, cisplatin IV over at least 2 hours on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery. Patients also undergo tissue biopsy and blood sample collection on study, and CT or MRI throughout the trial. |
Given IV
Andere Namen:
Undergo blood sample collection
Andere Namen:
Given IV
Andere Namen:
Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Undergo surgery Undergo tissue biopsy
Andere Namen:
Given Iv
Andere Namen:
Given via injection
Andere Namen:
Given Iv
Andere Namen:
|
|
Experimental: Arm C (durvalumab, gemcitabine hydrochloride)
Patients receive durvalumab IV over 60 minutes on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery. Patients also undergo tissue biopsy and blood sample collection on study, and CT or MRI throughout the trial. |
Undergo blood sample collection
Andere Namen:
Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Given IV
Andere Namen:
Undergo surgery Undergo tissue biopsy
Andere Namen:
Given IV
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Event-free survival (EFS) (Cisplatin eligible cohort: Arms A and B)
Zeitfenster: From registration/randomization to the earliest of systemic recurrence outside urinary tract, cancer progression, or death from any cause, assessed up to 5 years
|
Disease progression prior to surgery or omission of surgery due to unresectable tumors, muscle-invasive cancer or disease recurring outside of the bladder, urethra, or contralateral upper tract are considered as events for EFS. |
From registration/randomization to the earliest of systemic recurrence outside urinary tract, cancer progression, or death from any cause, assessed up to 5 years
|
|
Pathologic complete response (pCR) (Cisplatin ineligible cohort: Arm C)
Zeitfenster: At surgery
|
Will assess pathologic complete response at surgery (pCR, pT0N0/Nx) by local pathology review. Patients who drop out prior to surgery or who have unknown response status will be considered as non-responders. |
At surgery
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
pCR (für Cisplatin geeignete Kohorte: Arme A und B)
Zeitfenster: Bis zu 5 Jahre
|
Bis zu 5 Jahre
|
|
|
EFS (cisplatin-ineligible cohort: Arm C)
Zeitfenster: From registration/randomization to the earliest of systemic recurrence outside urinary tract, cancer progression, or death from any cause, assessed up to 5 years
|
Will be characterized using the Kaplan-Meier method. |
From registration/randomization to the earliest of systemic recurrence outside urinary tract, cancer progression, or death from any cause, assessed up to 5 years
|
|
Overall survival (OS) (All Patients)
Zeitfenster: From registration/randomization to death from any cause, assessed up to 5 years
|
OS will be evaluated by arm, post chemotherapy response (ypCR, stage yp =< T1N0, yp >= T2N0), as well as stage (ypCR and > ypCR) within and across treatment arms. Will be estimated using Kaplan-Meier method. |
From registration/randomization to death from any cause, assessed up to 5 years
|
|
Urothelial cancer-free survival or disease-free survival (All Patients)
Zeitfenster: From the date of surgery to the earlier of a return of upper tract urothelial cancer (UTUC) or death from any cause, assessed up to 5 years
|
A return of UTUC includes non-muscle invasive recurrences, pathologic T2 or higher muscle-invasive recurrences specifically in the urinary tract, metastatic disease outside the urinary tract, or death. Patients alive without documented UTUC will be censored at the date of last disease assessment. |
From the date of surgery to the earlier of a return of upper tract urothelial cancer (UTUC) or death from any cause, assessed up to 5 years
|
|
Cancer-specific survival (All Patients)
Zeitfenster: From registration/randomization to death due to cancer; deaths due to other causes will be counted as competing events, assessed up to 5 years
|
Will be analyzed using Gray's method and cumulative incidence estimates will be reported. |
From registration/randomization to death due to cancer; deaths due to other causes will be counted as competing events, assessed up to 5 years
|
|
Renal function outcomes following systemic treatment and following radical nephroureterectomy (All Patients)
Zeitfenster: Post chemotherapy and post surgery
|
The proportion of patients with renal insufficiency (creatinine [CrCl] < 60 ml/min) post chemotherapy and post nephroureterectomy as well as the proportion of patients with renal function improvement (CrCl < 60 ml/min at baseline and CrCl >= 60 ml/min on study) will be reported along with exact binomial confidence intervals. The distribution of changes in renal function post chemotherapy as well as post surgery from baseline will also be reported. The analysis of renal function outcomes will be performed among patients who receive at least one dose of study therapy. |
Post chemotherapy and post surgery
|
|
Incidence of adverse events (All Patients)
Zeitfenster: Up to 30 days post surgery
|
Toxicity will be evaluated in all treated patients. |
Up to 30 days post surgery
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Jean H Hoffman-Censits, ECOG-ACRIN Cancer Research Group
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Aminosäuren, Peptide und Proteine
- Proteine
- Schwefelverbindungen
- Organische Chemikalien
- Heterocyclische Verbindungen, 1-Ring
- Heterocyclische Verbindungen
- Heterocyclische Verbindungen, 2-Ring
- Heterocyclische Verbindungen, Fusionsring
- Untersuchungstechniken
- Klinische Labortechniken
- Diagnosetechniken und Verfahren
- Diagnose
- Chirurgische Eingriffe, operativ
- Zytologische Techniken
- Zytodiagnose
- Kohlenwasserstoffe
- Kohlenwasserstoffe, zyklisch
- Kohlenhydrate
- Alkaloide
- Polycyclische aromatische Kohlenwasserstoffe
- Kohlenwasserstoffe, aromatisch
- Polycyclische Verbindungen
- Glykoside
- Indolen
- Antikörper
- Immunglobuline
- Immunoproteine
- Blutproteine
- Serumglobuline
- Globuline
- Anorganische Chemikalien
- Chlorverbindungen
- Stickstoffverbindungen
- Desoxycytidin
- Cytidin
- Pyrimidin -Nucleoside
- Pyrimidine
- Elemente
- Metalle
- Diagnosetechniken, chirurgisch
- Chemie -Techniken, analytisch
- Spektrumanalyse
- Pterins
- Pteridine
- Metalle, schwer
- Vinca -Alkaloide
- Secologanin Tryptaminalkaloide
- Indolalkaloide
- Indolizidine
- Indoliziner
- Aminopterin
- Anthracyclines
- Naphthatene
- Aminoglykoside
- Immunglobulinisotypen
- Sulfide
- Anionen
- Ionen
- Elektrolyte
- Schwefelwasserstoff
- Platinverbindungen
- Daunorubicin
- Übergangselemente
- Gemcitabin
- Methotrexat
- Doxorubicin
- Immunglobulin G
- Cisplatin
- Vinblastin
- 1,2-Diaminocyclohexanplatin-II-Citrat
- Biopsie
- Handhabung von Proben
- Magnetresonanzspektroskopie
- Durvalumab
- Disulfide
- Platin
- Merphos
- Pegfilgrastim
- pegylierter Granulozyten-Kolonie-stimulierender Faktor
Andere Studien-ID-Nummern
- NCI-2020-09850
- U10CA180820 (US NIH Stipendium/Vertrag)
- NCI-2020-09850 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
- EA8192 (Andere Kennung: CTEP)
- EA8192 (Andere Kennung: ECOG-ACRIN Cancer Research Group)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .